52 related articles for article (PubMed ID: 21883692)
1. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer.
Fujie H; Tanaka T; Tagawa M; Kaijun N; Watanabe M; Suzuki T; Nakayama K; Numasaki M
Cancer Sci; 2011 Nov; 102(11):1977-90. PubMed ID: 21883692
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation.
Wang R; Zhang T; Lu Y; Lin Y; Kou S; Li X; Wang Y; Xie L
Cell Immunol; 2023; 393-394():104782. PubMed ID: 37931572
[TBL] [Abstract][Full Text] [Related]
3. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.
Nakashima H; Miyake K; Clark CR; Bekisz J; Finbloom J; Husain SR; Baron S; Puri RK; Zoon KC
Cancer Immunol Immunother; 2012 Jul; 61(7):1081-92. PubMed ID: 22159517
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
Wen Z; Jia Q; Kang X; Lou Y; Zou L; Yang J; Gao J; Han L; Li X
Anticancer Drugs; 2017 Jan; 28(1):31-39. PubMed ID: 27759573
[TBL] [Abstract][Full Text] [Related]
5. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.
Fleischmann CM; Stanton GJ; Fleischmann WR
Cancer Immunol Immunother; 1994 Sep; 39(3):148-54. PubMed ID: 7923244
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway.
Zhang F; Shang D; Zhang Y; Tian Y
PLoS One; 2011; 6(5):e20382. PubMed ID: 21625390
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
Bielefeldt-Ohmann H; Marzo AL; Himbeck RP; Jarnicki AG; Robinson BW; Fitzpatrick DR
Cancer Immunol Immunother; 1995 Apr; 40(4):241-50. PubMed ID: 7750122
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model.
Vasquez M; Paredes-Cervantes V; Aranda F; Ardaiz N; Gomar C; Berraondo P
Oncotarget; 2017 Jan; 8(3):5247-5255. PubMed ID: 28029653
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects.
Matsuyama H; Yoshihiro S; Ohmoto Y; Yamamoto N; Naito K
Cancer Immunol Immunother; 1993 Jul; 37(2):84-8. PubMed ID: 8319245
[TBL] [Abstract][Full Text] [Related]
10. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Tagliaferri P; Caraglia M; Budillon A; Marra M; Vitale G; Viscomi C; Masciari S; Tassone P; Abbruzzese A; Venuta S
Cancer Immunol Immunother; 2005 Jan; 54(1):1-10. PubMed ID: 15693134
[TBL] [Abstract][Full Text] [Related]
11. Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment.
He H; Grignol V; Karpa V; Yen C; LaPerle K; Zhang X; Jones NB; Liang MI; Lesinski GB; Ho WS; Carson WE; Lee LJ
J Control Release; 2011 May; 151(3):239-45. PubMed ID: 21362447
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.
Plote D; Choi W; Mokkapati S; Sundi D; Ferguson JE; Duplisea J; Parker NR; Yla-Herttuala S; Committee SCB; McConkey D; Schluns KS; Dinney CP
Oncoimmunology; 2019; 8(5):e1577125. PubMed ID: 31069136
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative Properties of Type I and Type II Interferon.
Bekisz J; Baron S; Balinsky C; Morrow A; Zoon KC
Pharmaceuticals (Basel); 2010 Mar; 3(4):994-1015. PubMed ID: 20664817
[TBL] [Abstract][Full Text] [Related]
14. Regulation of type I and type III interferon induction in response to pathogen sensing.
Gewaid H; Bowie AG
Curr Opin Immunol; 2024 May; 87():102424. PubMed ID: 38761566
[TBL] [Abstract][Full Text] [Related]
15. Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.
Mizumori O; Zembutsu H; Kato Y; Tsunoda T; Miya F; Morizono T; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Akaza H; Nakamura Y
Exp Ther Med; 2010 Nov; 1(6):955-961. PubMed ID: 22993625
[TBL] [Abstract][Full Text] [Related]
16. IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function.
Broggi A; Tan Y; Granucci F; Zanoni I
Nat Immunol; 2017 Oct; 18(10):1084-1093. PubMed ID: 28846084
[TBL] [Abstract][Full Text] [Related]
17. New treatment alternatives for primary and metastatic colorectal cancer by an integrated transcriptome and network analyses.
Karaca C; Demir Karaman E; Leblebici A; Kurter H; Ellidokuz H; Koc A; Ellidokuz EB; Isik Z; Basbinar Y
Sci Rep; 2024 Apr; 14(1):8762. PubMed ID: 38627442
[TBL] [Abstract][Full Text] [Related]
18. Heterologous Expression of Human IFNγ and Anti-IL17 Antibody in Leishmania tarentolae Promastigote.
Rouzbahani AK; Hosseini SZ; Bandehpour M; Kazemi B; Tavasoli A; Mamaghani AJ; Kheirandish F
Acta Parasitol; 2024 Mar; ():. PubMed ID: 38536611
[TBL] [Abstract][Full Text] [Related]
19. Enhanced soluble expression of active recombinant human interleukin-29 using champion pET SUMO system.
Munir A; Ahmed N; Akram M; Fujimura NA; Tahir S; Malik K
Biotechnol Lett; 2023 Aug; 45(8):1001-1011. PubMed ID: 37266881
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer.
Zhao Y; Jia S; Zhang K; Zhang L
Front Oncol; 2023; 13():1064616. PubMed ID: 36874133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
